SecBot SecBot
SECBOTREPLAY Home › Report › ARVN

ARVN · Arvinas announced positive Phase 1 clinical trial data for ARV-102,…

ARVINAS, INC. · 8-K filed Mar 18, 2026 at 07:07 ET

At the news

BULLISHIMPACT 7/10

8-K filed Mar 18, 2026 at 07:07 ET

Arvinas announced positive Phase 1 clinical trial data for ARV-102, showing greater than 50% degradation of LRRK2 in cerebrospinal fluid of Parkinson's disease patients, with the drug well-tolerated across all doses. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential for a registrational trial in late 2026.

  • ARV-102 demonstrated >50% LRRK2 degradation in CSF at all doses by day 14, maintained through day 28
  • Multiple oral doses of ARV-102 (20mg, 40mg, 80mg) were well tolerated with no serious adverse events
  • Data presented at AD/PD 2026 conference in Copenhagen
  • Company plans to initiate Phase 1b trial in progressive supranuclear palsy in Q2 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access